Figures used were reported by each company in their annual 10K SEC filing
It's great to know that you appreciate her attentive listening and educational approach
Safety considerations Available evidence suggests that combined therapy with SGLT2 inhibitors and GLP-1 receptor agonists is generally well tolerated, with safety profiles largely consistent with those of each class individually [24, 40,41,42,43]
Sun Y, Bak B, Schoenmakers N, van Trotsenburg AS, Oostdijk W, Voshol P, Cambridge E, White JK, le Tissier P, Gharavy SN, Martinez-Barbera JP, Stokvis-Brantsma WH, Vulsma T, Kempers MJ, Persani L, Campi I, Bonomi M, Beck-Peccoz P, Zhu H, Davis TM, Hokken-Koelega AC, Del Blanco DG, Rangasami JJ, Ruivenkamp CA, Laros JF, Kriek M, Kant SG, Bosch CA, Biermasz NR, Appelman-Dijkstra NM, Corssmit EP, Hovens GC, Pereira AM, den Dunnen JT, Wade MG, Breuning MH, Hennekam RC, Chatterjee K, Dattani MT, Wit JM, Bernard DJ
With so many conflicting opinions floating aroundfrom glowing testimonials to sceptical dermatologistsit's no wonder you're confused
